News stories about Cryolife (NYSE:CRY) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cryolife earned a coverage optimism score of 0.25 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 46.3503739349246 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

A number of equities analysts have recently issued reports on CRY shares. Canaccord Genuity reiterated a “buy” rating and issued a $25.00 price target on shares of Cryolife in a report on Monday, October 9th. Zacks Investment Research upgraded shares of Cryolife from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Northland Securities reiterated a “buy” rating and issued a $23.50 price target on shares of Cryolife in a report on Monday, November 13th. TheStreet downgraded shares of Cryolife from a “b” rating to a “c+” rating in a report on Monday, October 30th. Finally, Lake Street Capital increased their price target on shares of Cryolife to $26.00 and gave the company a “buy” rating in a report on Wednesday, October 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. Cryolife presently has a consensus rating of “Buy” and a consensus price target of $23.63.

Cryolife (CRY) opened at $17.65 on Tuesday. The company has a quick ratio of 4.90, a current ratio of 5.96 and a debt-to-equity ratio of 0.29. The stock has a market cap of $610.60, a PE ratio of 63.04 and a beta of 0.77. Cryolife has a twelve month low of $14.02 and a twelve month high of $24.00.

In other news, VP David C. Gale sold 20,000 shares of the stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $19.63, for a total value of $392,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Amy Horton sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total transaction of $76,000.00. Following the transaction, the chief accounting officer now owns 98,705 shares of the company’s stock, valued at $1,875,395. The disclosure for this sale can be found here. Insiders sold a total of 58,190 shares of company stock valued at $1,119,210 in the last quarter. Insiders own 6.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-cryolife-cry-share-price/1848769.html.

Cryolife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.